Overview

Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this pharmacokinetic (PK) and pharmacodynamic (PD) study is: To study the rate and duration of serum cidal activity of caspofungin (CFG) and micafungin (MFG) against Candida isolates from the subject and against Candida glabrata with varying degrees of caspofungin susceptibilities. This investigation will provide clinicians information supporting the use of caspofungin and micafungin in situations where Candida strains may be a cause of infection.
Phase:
Phase 4
Details
Lead Sponsor:
Gary E. Stein, Pharm.D.
Collaborator:
Astellas Pharma US, Inc.
Treatments:
Caspofungin
Echinocandins
Micafungin